Physician profile
Krishna Bhat
NPI 1205870797
$7,490.75
in general payments reported to CMS, 2019-2025
34 companies · $2,208 in 2025
The $2,208 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,042 · 2020: $269 · 2021: $298 · 2022: $711 · 2023: $1,232 · 2024: $1,731 · 2025: $2,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,171.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $946.90 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $757.49 | 2019-2025 | |
| Pfizer INC. | $738.24 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $696.06 | 2019-2025 | Farxiga, Wainua, Fasenra |
| Amgen INC. | $602.10 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $497.69 | 2021-2025 | Verquvo, Capvaxive |
| Boston Scientific Corporation | $486.83 | 2020-2025 | Emblem Mri S-Icd, Watchman Flx, S-Icd System Magnet |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $484.88 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.28 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $225.85 | 2019-2024 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $186.02 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $165.92 | 2021-2025 | |
| Irhythm Technologies, INC. | $125.03 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Akcea Therapeutics, INC. | $124.43 | 2019 | |
| Sanofi-Aventis U.S. LLC | $118.38 | 2019-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $112.19 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abiomed | $100.01 | 2024-2025 | Impella |
| Regeneron Healthcare Solutions, INC. | $97.53 | 2019-2024 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $89.31 | 2020-2025 | Opsumit, Uptravi |
| Atricure, INC. | $88.29 | 2019-2022 | |
| Daiichi Sankyo INC. | $84.11 | 2024-2025 | Injectafer |
| Amarin Pharma, INC. | $77.49 | 2019-2022 | |
| Inari Medical, INC. | $74.61 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Alnylam Pharmaceuticals INC. | $64.10 | 2024-2025 | Onpattro |
| W. L. Gore & Associates, INC. | $50.52 | 2022 | |
| Tactile Systems Technology INC | $49.15 | 2023-2024 | Flexitouch Plus, Entre Plus |
| Esperion Therapeutics, INC. | $45.59 | 2024-2025 | Nexletol |
| Scpharmaceuticals INC. | $36.83 | 2023-2024 | |
| Lilly USA, LLC | $33.73 | 2025 | Zepbound |
| Impulse Dynamics (USA) INC. | $29.52 | 2024 | Optimizer |
| Forte Bio-Pharma LLC | $24.99 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $19.35 | 2022 | |
| Bridgebio Pharma, INC. | $16.88 | 2025 | Attruby |
| Glaxosmithkline, LLC. | $14.45 | 2025 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishna Bhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.